This 2020 study by Wang et al. analyzed data from the Long Island Breast Cancer Study Project to assess the association between menopausal hormone therapy (MHT) use and long-term mortality outcomes. Among women with breast cancer, ever-users of MHT had a 23% lower risk of all-cause mortality (HR=0.77), a 31%
This 2020 study analyzed long-term data from the Women’s Health Initiative (WHI) to assess the impact of menopausal hormone therapy (MHT) on breast cancer incidence and mortality. Among 10,739 women with prior hysterectomy, those receiving conjugated equine estrogen (CEE) alone had a significantly lower breast cancer incidence (HR 0.78; 95%
This review examines the safety and benefits of menopausal hormone therapy (MHT), highlighting its effectiveness in alleviating vasomotor symptoms, preventing bone loss, and potentially offering cardiovascular benefits when initiated near menopause. The risk-benefit profile of MHT varies based on the timing of initiation, therapy type, and duration, with combined estrogen-progestogen
This review article examines the role of estrogen-based menopausal hormone therapy (MHT) in preventing postmenopausal bone loss and reducing fracture risk by exploring its dual mechanisms—suppressing osteoclast activity and enhancing osteoblast function—in a dose-dependent manner, with benefits seen even at ultra-low doses and through transdermal delivery. It discusses the clinical
